IMPORTANT DATES
SPEAKERS
-
ML01 Translating DNA Repair for Targeting Cancers Prof. Kyungjae Myung UNIST / Institute for Basic Science, Korea CV -
ML02 Biological Heterogeneity of AML: Implications for Prognosis and Treatment Prof. Clara Bloomfield The Ohio State University, USA CV -
ML03 Approaching Survival of the General Population: The Results of CML Study IV in the Global Context Prof. Rüdiger Hehlmann Heidelberg University, Germany CV -
ML04 New Models of Human Leukemia Dr. Connie Eaves British Columbia Cancer part of Provincial Health Services Authority, Canada CV -
ML05 Integrating CAR T-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes Prof. David G. Maloney Fred Hutchinson Cancer Research Center, USA CV -
ML06 Leukemia Stem Cell and Bone Marrow Microenvironment Interactions Prof. Ravi Bhatia The University of Alabama at Birmingham, USA CV -
ML07 Understanding Evolution and Outcomes in Myeloproliferative Neoplasms Dr. Jyoti Nangalia Wellcome Sanger Institute, UK CV -
KS A Novel Epigenetic Drug against Adult T-cell Leukemia Prof. Toshiki Watanabe The University of Tokyo, Japan CV -
SY01-1 Using HTLV-1/BLV Genomics to Understand Adult T-cell Leukemia Dr. Anne Van den Broeke Jules Bordet Institute - ULB, Belgium -
SY01-2 Hydroa-vacciniforme-like Lymphoproliferative Disease: A Cutaneous Form of CAEBV Prof. Young-Hyeh Ko Sungkyunkwan University, Korea -
SY01-3 Can We Cure Adult T Cell Leukemia/Lymphoma? Prof. Ali Bazarbachi American University of Beirut-Medical Center, Lebanon CV -
SY02-1 DNA Methylation and Hydroxymethylation in Hematologic Differentiation and Transformation Prof. Myunggon Ko Ulsan National Institute of Science and Technology, Korea CV -
-
-
SY02-4 Hypomethylation-based Combination Treatments: Where Epigenetics Meets Immunotherapy Prof. Michael Lübbert University of Freiburg Medical Center, Germany CV -
-
SY03-1 The Rapidly Evolving Landscape in AML Prof. Gert Ossenkoppele Amsterdam University Medical Center, location VUMC, The Netherlands CV -
SY03-2 Curative Treatment Options for Older Patients with AML Prof. Hervé Dombret Saint-Louis Institute for Research/ University of Paris, France CV -
-
SY03-4 Functional Genomic Approaches to Identifying New Therapeutic Strategies for AML Prof. Jeffrey Tyner Oregon Health & Science University, USA CV -
SY04-1 Next Generation Sequencing for Chronic Myeloid Leukemia Prof. Susan Branford Centre for Cancer Biology, SA Pathology, Australia CV -
SY04-2 New Horizon for CML Therapy: Treatment Discontinuation (TFR) Prof. Giuseppe Saglio University of Torino, Italy CV -
-
SY04-4 Allogeneic Stem Cell Transplantation in CML Prof. Eduardo Olavarria Imperial College London, UK CV -
SY05-1 Clinical and Biological Significance of RNA Editing Defect in Myeloma Prof. Wee Joo Chng National University Health System, Singapore CV -
SY05-2 Current Approaches and Future Perspectives in the Treatment of Newly Diagnosed Myeloma Patients Prof. Roberto Mina University of Torino, Italy CV -
SY05-3 MRD: A Pitfall Between Next Generation Flow and Next Generation Sequencing Prof. Dong Soon Lee Seoul National University, Korea CV -
SY06-1 Analysis of CNS-ALL with Patient Derived Xenografts (PDX) Model Prof. Itaru Kato Kyoto University, Japan CV -
SY06-2 Targeting Cell Adhesion-mediated Resistance in ALL Prof. Yong-Mi Kim University of Southern California, USA CV -
SY06-3 Minimal Residual Disease and Targeted Therapy in Acute Lymphoblastic Leukemia Prof. Dieter Hoelzer Onkologikum Frankfurt, Germany CV -
-
LS02 Cutting Edge of Molecular Target Therapy and Therapeutic Strategies in CML Prof. Yosuke Minami National Cancer Center Hospital East, Japan CV -
SY07-1 Understanding and Targeting the Stem Cell Origins of MDS and AML Prof. Ulrich Steidl Albert Einstein College of Medicine - Montefiore Medical Center, USA CV -
SY07-2 Genetics and Mechanisms of Chemotherapy Resistance in ALL Prof. Adolfo Ferrando Columbia University, USA CV -
SY07-3 TBD Prof. Seishi Ogawa Kyoto University, Japan -
SY07-4 Single-cell Sequencing for Understanding Tumor Heterogeneity and Evolution Prof. Semin Lee Ulsan National Institute of Science and Technology, Korea CV -
SY08-1 Molecular Predictors and Prognosticators for the Clinical Management of Chronic Lymphocytic Leukemia Prof. Gianluca Gaidano University of Eastern Piedmont, Italy CV -
-
-
-
SY09-1 2020 Clinical, Laboratory, Molecular and Bone Marrow (CLMB) Classification and Treatment Options of Myeloproliferative Neoplasms Prof. Jan Jacques Michiels Goodheart Institute and Foundation, The Netherlands CV -
SY09-2 Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis Prof. Ki-Seong Eom The Catholic University of Korea, Korea -
-
SY10-1 Study of Hematopoiesis Using Zebrafish Model System Dr. Yoonsung Lee UNIST / Institute for Basic Science, Korea CV -
SY10-2 Nutrient Supply Specific to Chronic Myelogenous Leukemia Stem Cells Dr. Kazuhito Naka Hiroshima University, Japan CV -
-
SY10-4 TBD Prof. Jae Park Memorial Sloan Kettering Cancer Center, USA
